To demonstrate this hypothesis, we tested several immunomodulatory candidates (TLR2 ligands), that have those properties in vitro, on CDH animal models and found that TLR2/4 ligands have a significant curative effect. The gene discussed is TLR2; the disease is congenital diaphragmatic hernia.